A Phase 2 interventional study of 75mg SHP647 (PF-00547659) and 225mg SHP647 (PF-00547659) in Ulcerative Colitis, sponsored by Shire. Completed at 99 sites in 21 countries. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2021-06-03.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Colitis, Ulcerative by Takeda — 6 open to participants now, 10 under way, 5 of them phase 3. Colitis, Ulcerative · Takeda.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 16th largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2013, is one of 10 in phase 2, and was the 15th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →6 of the 68 studies in Colitis, Ulcerative by Takeda are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States, China, Czechia and 5 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in Korea, Republic of
Ages 18+
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 66 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 330 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 240 across the 43 interventional studies, 372 across the 24 observational. Of the 54 that completed or were terminated, 35 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
4 of the studies in Colitis, Ulcerative by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
| NCT05428345TakedaA Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 68 studies in Colitis, Ulcerative by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 144 weeks of open-label treatment to evaluate the long-term safety of the drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 75 milligrams (mg) of SHP647 subcutaneous (SC) injection every 4 weeks for 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen. During the first 72 weeks, a one time dose escalation to 225 mg of SHP647 SC injection every 4 weeks is allowed after 8 weeks of the study for participants who experience clinical deterioration or unacceptably low level of response to the investigational product. The decision to escalate will be guided by the response and relapse criteria tempered by clinical judgment. Following the first 72 weeks, participants will receive 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
Drug: 75mg SHP647 (PF-00547659)
Participants will receive 225 mg of SHP647 SC injection every 4 weeks for 72 weeks followed by 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
Drug: 225mg SHP647 (PF-00547659)
75 mg sterile liquid injected subcutaneously every 4 weeks.
225 mg sterile liquid injected subcutaneously every 4 weeks.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant who was administered a product or medical device; the event did not need to necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death, was life threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect. Number of participants with TEAEs, STEAEs, and those withdrew from treatment due to TEAEs were reported.
Time frame: From start of study drug administration up to 168 weeks
Percentage of Participants With Mucosal Healing at Week 16
Mucosal healing was defined as an absolute Mayo subscore for endoscopy of 0 or 1 (based on centrally read score) as assessed by flexible sigmoidoscopy or colonoscopy. The Mayo score is a tool designed to measure disease activity for ulcerative colitis (UC). The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, findings on flexible sigmoidoscopy, and physician's global assessment \[PGA\]) each graded 0 to 3 with the higher score indicating more severe disease activity. The percentage of participants with mucosal healing at week 16 was reported.
Time frame: Week 16
Serum Trough Concentrations of SHP647 Versus Time
Serum trough concentrations of SHP647 versus time was reported.
Time frame: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72 and 156
Number of Participants With Positive Anti-drug (SHP647) Antibodies (ADA)
The anti-drug antibodies (ADA) positive was defined as ADA log base 2 titer greater than or equal to (\>=) 4.64. The number of participants with positive ADA was reported.
Time frame: Baseline, Week 8, 16, 24, 40, 48, 64 and 156
Number of Participants With Positive Neutralizing Antibodies (NAb)
The positive Neutralizing Antibodies (NAb) was defined as NAb titer greater than or equal to (\>=) 0.903. The number of participants with NAb was reported. Here "inconclusive" refers to participants who were neither reported as positive nor negative for NAb and anti-drug antibodies (ADA) positive was defined as ADA log base 2 titer greater than or equal to (\>=) 4.64.
Time frame: Baseline, Week 8, 16, 24, 40, 48, 64 and 156
The study was conducted at 101 centers in 21 countries between 18 Mar 2013 (first participant first visit) and 13 Dec 2017 (last participant last visit).
| Milestone | SHP647 75 mg | SHP647 225 mg |
|---|---|---|
| Started | 164 | 166 |
| Completed | 93 | 83 |
| Not completed | 71 | 83 |
| Withdrew: Adverse event | 4 | 12 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 34 | 42 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Other (insufficient clinical response) | 22 | 20 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Other (other) | 9 | 5 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant who was administered a product or medical device; the event did not need to necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death, was life threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect. Number of participants with TEAEs, STEAEs, and those withdrew from treatment due to TEAEs were reported.
| Participants | SHP647 75 mg | SHP647 225 mg |
|---|---|---|
| Participants with any TEAE | 146 | 147 |
| Participants with any TESAE | 34 | 40 |
| Participants who withdrew treatment due to TEAE | 12 | 23 |
Mucosal healing was defined as an absolute Mayo subscore for endoscopy of 0 or 1 (based on centrally read score) as assessed by flexible sigmoidoscopy or colonoscopy. The Mayo score is a tool designed to measure disease activity for ulcerative colitis (UC). The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, findings on flexible sigmoidoscopy, and physician's global assessment \[PGA\]) each graded 0 to 3 with the higher score indicating more severe disease activity. The percentage of participants with mucosal healing at week 16 was reported.
| Percentage of participants | SHP647 75 mg | SHP647 225 mg |
|---|---|---|
| Percentage of Participants With Mucosal Healing at Week 16 | 27.4 | 29.5 |
Serum trough concentrations of SHP647 versus time was reported.
| Micrograms/liter (ug/L) | SHP647 75 mg | SHP647 225 mg |
|---|---|---|
| Baseline | 6398.62 ± 8584.412 | 8064.41 ± 10629.768 |
| Week 4 | 5496.56 ± 4026.759 | 16787.31 ± 7807.292 |
| Week 8 | 6245.79 ± 3371.708 | 20345.29 ± 9286.956 |
| Week 12 | 9038.72 ± 5540.836 | 23915.87 ± 10434.073 |
| Week 16 | 10445.24 ± 6387.004 | 24772.35 ± 11970.153 |
| Week 20 | 10928.76 ± 7900.859 | 25582.98 ± 11767.775 |
| Week 24 | 11145.54 ± 8019.864 | 27832.20 ± 12469.086 |
| Week 28 | 12978.11 ± 8772.285 | 27797.77 ± 13070.361 |
| Week 32 | 12926.04 ± 8798.671 | 28381.93 ± 11748.573 |
| Week 36 | 12785.55 ± 9182.501 | 29666.64 ± 13997.231 |
| Week 40 | 13004.90 ± 9544.675 | 28947.34 ± 12151.971 |
| Week 44 | 13337.50 ± 8620.549 | 29855.69 ± 13605.897 |
| Week 48 | 14061.44 ± 9257.991 | 30010.61 ± 14014.183 |
| Week 52 | 14192.83 ± 9326.176 | 28917.76 ± 14545.617 |
| Week 56 | 15179.77 ± 10405.996 | 29985.88 ± 14122.172 |
| Week 60 | 15133.54 ± 9673.602 | 29086.78 ± 12606.888 |
| Week 64 | 15354.29 ± 10112.098 | 31613.08 ± 13712.478 |
| Week 68 | 15584.38 ± 10407.781 | 30609.08 ± 14331.857 |
| Week 72 | 15006.48 ± 9390.020 | 31342.89 ± 14012.311 |
| Week 156 | 983.49 ± 1485.708 | 1893.88 ± 4530.680 |
The anti-drug antibodies (ADA) positive was defined as ADA log base 2 titer greater than or equal to (\>=) 4.64. The number of participants with positive ADA was reported.
| Participants | SHP647 75 mg | SHP647 225 mg |
|---|---|---|
| Baseline | 9 | 10 |
| Week 8 | 3 | 1 |
| Week 16 | 1 | 1 |
| Week 24 | 1 | 1 |
| Week 40 | 1 | 2 |
| Week 48 | 1 | 0 |
| Week 64 | 1 | 0 |
| Week 156 | 0 | 1 |
The positive Neutralizing Antibodies (NAb) was defined as NAb titer greater than or equal to (\>=) 0.903. The number of participants with NAb was reported. Here "inconclusive" refers to participants who were neither reported as positive nor negative for NAb and anti-drug antibodies (ADA) positive was defined as ADA log base 2 titer greater than or equal to (\>=) 4.64.
| Participants | SHP647 75 mg | SHP647 225 mg |
|---|---|---|
| Baseline: Without +ADA | 139 | 143 |
| Baseline: With +ADA, with +NAb | 0 | 4 |
| Baseline: With +ADA, without +NAb | 0 | 1 |
| Baseline: With +ADA, with inconclusive NAb | 8 | 5 |
| Baseline: With +ADA, missing NAb | 1 | 0 |
| Week 8: Without +ADA | 140 | 150 |
| Week 8: With +ADA, with +NAb | 1 | 1 |
| Week 8: With +ADA, without +NAb | 2 | 0 |
| Week 16: Without +ADA | 139 | 143 |
| Week 16: With +ADA, with +NAb | 0 | 1 |
| Week 16: With +ADA, without +NAb | 1 | 0 |
| Week 24: Without +ADA | 105 | 118 |
| Week 24: With +ADA, with +NAb | 0 | 1 |
| Week 24: With +ADA, without +NAb | 1 | 0 |
| Week 40: Without +ADA | 93 | 102 |
| Week 40: With +ADA, with +NAb | 1 | 2 |
| Week 40: With +ADA, without +NAb | 0 | 0 |
| Week 48: Without +ADA | 96 | 92 |
| Week 48: With +ADA, with +NAb | 1 | 0 |
| Week 48: With +ADA, without +NAb | 0 | 0 |
| Week 64: Without +ADA | 82 | 86 |
| Week 64: With +ADA, with +NAb | 0 | 0 |
| Week 64: With +ADA, without +NAb | 1 | 0 |
| Week 156: Without +ADA | 73 | 80 |
| Week 156: With +ADA, with +NAb | 0 | 0 |
| Week 156: With +ADA, without +NAb | 0 | 1 |
Collected over From start of study drug administration up to 168 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SHP647 75 mg | 1/164 (0.6%) | 34/164 (20.7%) | 116/164 (70.7%) |
| SHP647 225 mg | 0/166 (0%) | 40/166 (24.1%) | 119/166 (71.7%) |
| Event | SHP647 75 mg | SHP647 225 mg |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 15/164 | 18/166 |
| AnaemiaBlood and lymphatic system disorders | 2/164 | 1/166 |
| GastroenteritisInfections and infestations | 2/164 | 1/166 |
| DehydrationMetabolism and nutrition disorders | 0/164 | 2/166 |
| HeadacheNervous system disorders | 0/164 | 2/166 |
| Serous cystadenocarcinoma ovaryNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/164 | 0/166 |
| Retinal detachmentEye disorders | 1/164 | 0/166 |
| DiarrhoeaGastrointestinal disorders | 1/164 | 0/166 |
| Duodenal ulcerGastrointestinal disorders | 1/164 | 0/166 |
| EnteritisGastrointestinal disorders | 1/164 | 0/166 |
| Event | SHP647 75 mg | SHP647 225 mg |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 41/164 | 36/166 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 27/164 | 29/166 |
| NasopharyngitisInfections and infestations | 20/164 | 28/166 |
| Upper respiratory tract infectionInfections and infestations | 23/164 | 20/166 |
| HeadacheNervous system disorders | 17/164 | 21/166 |
| CoughRespiratory, thoracic and mediastinal disorders | 20/164 | 11/166 |
| Abdominal painGastrointestinal disorders | 9/164 | 20/166 |
| NauseaGastrointestinal disorders | 8/164 | 19/166 |
| GastroenteritisInfections and infestations | 18/164 | 13/166 |
| Back painMusculoskeletal and connective tissue disorders | 12/164 | 18/166 |
Safety analysis set (SAS) consisted of all enrolled participants who had received at least 1 dose of SHP647.
| Age, Continuous(Years) | SHP647 75 mg | SHP647 225 mg | Total |
|---|---|---|---|
| Mean | 40.5 ± 12.75 | 41.1 ± 13.68 | 40.8 ± 13.21 |
| Sex: Female, Male(Participants) | SHP647 75 mg | SHP647 225 mg | Total |
|---|---|---|---|
| Female | 62 | 70 | 132 |
| Male | 102 | 96 | 198 |
| Ethnicity (NIH/OMB)(Participants) | SHP647 75 mg | SHP647 225 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 6 | 10 |
| Not Hispanic or Latino | 160 | 160 | 320 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | SHP647 75 mg | SHP647 225 mg | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 |
| Race — Asian | 11 | 15 | 26 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Race — Black or African American | 3 | 2 | 5 |
| Race — White | 148 | 143 | 291 |
| Race — More than one race | 0 | 0 | 0 |
| Race — Other | 2 | 6 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2013 to primary completion in Dec 2017, 56 months.
Results were first posted in Apr 2019, 1 year 4 months after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 56 months is above that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ontamalimab